Abstract
Purpose :
Poor patient adherence to topical intraocular pressure (IOP)-lowering medication can complicate management of open-angle glaucoma (OAG) and lead to worse outcomes. The intracameral Bimatoprost SR implant mitigates many of the adherence challenges associated with eye drops. Clinical trials have demonstrated its efficacy and safety, but there is minimal data on its real-world utilization and outcomes. This study evaluates the real-world utilization and effectiveness of Bimatoprost SR implant in patients with OAG or ocular hypertension.
Methods :
Using Symphony Health Solutions Integrated Dataverse®, an administrative claims database, bilateral recipients of intracameral Bimatoprost SR implants between June 2020 to April 2022 were identified and stratified by disease severity. Two claims for Bimatoprost SR implant ≤2 months apart, a proxy for bilateral, single-implant treatment, were required. Patient demographic and clinical characteristics, topical IOP-lowering medication use, and time to next treatment (TTNT) were evaluated.
Results :
792 patients with two claims ≤2 months (mean 14.5 days) apart were followed for an average of 8.3 months. Patients had a mean (standard deviation [SD]) age of 73.9 (7.0) years. Most (93.8%) had a primary diagnosis of OAG (mild, moderate and severe in 32.3%, 38.1% and 24.5% of patients, respectively); 32.3% had concurrent ocular surface disease. The proportion of drop-free patients increased from 27% to 59% post implant, and the mean number of classes of topical medication per patient decreased by 0.62. Median TTNT (topical drop or glaucoma procedure) was 8.2 months (12.7, 8.2, and 4.9 months for patients with mild, moderate, and severe OAG, respectively).
Conclusions :
Analysis of real-world claims data indicates that treatment with a single Bimatoprost SR implant reduces topical medication burden and may provide durable IOP control for up to 13 months, based on TTNT findings. Real-world patients receiving Bimatoprost SR implant are typically older and have more severe OAG than patients in the registration trial. Earlier intervention with Bimatoprost SR implant in clinical practice may be appropriate to ensure optimal therapeutic benefit.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.